Evidence map›Paper›PMID 40224196›Full record

ReviewJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences2024

Regenerative mechanisms of stem cells and their clinical applications for degenerative eye diseases.

Baodong Zhang, Shusong Gao, Shibo Liu, Xuewu Gong, Jing Wu, Yu Zhang, Li Ma, Lijie Sheng

Abstract readReview
In one paragraph

Review in Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Baodong Zhang *Department of Ophthalmology, Hulun Buir Aier Eye Hospital, Hulunbuir, Inner Mongolia, China.
Shusong Gao *Department of Ophthalmology, Ezhou Central Hospital, Ezhou, Hubei, China.
Shibo LiuDepartment of Ophthalmology, Hulun Buir Aier Eye Hospital, Hulunbuir, Inner Mongolia, China.
Xuewu GongDepartment of Ophthalmologic, The Second Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang, China.
Jing WuDepartment of Ophthalmologic, The Second Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang, China.
Yu ZhangDepartment of Ophthalmologic, The Second Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang, China.
Li MaDepartment of Ophthalmologic, The Second Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang, China.
Lijie ShengDepartment of Ophthalmologic, The Second Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are different types of treatment for eye diseases. Although the majority of eye diseases are curable with primary treatments and surgery, some of degenerative eye damages need regeneration that is not gained by conventional procedures. Stem cells, such as mesenchymal stem cells, human embryonic stem cell-derived retinal pigmented epithelium, and inducible pluripotent stem cells, are now considered one of the most important and safe methods for regeneration of various damaged tissues or organs. However, how will stem cell therapy contribute to regeneration and overcome degenerative eye diseases? This review discusses the regenerative mechanisms, clinical applications, and advantages of different types of stem cells for restoring degenerative eye diseases.

Indexed as

Eye diseasesmesenchymal stem cellsregenerationstem cells

Identifiers

PMID40224196
PMCPMC11992415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.